Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase

Molecular Therapy

Volumn 25, Issue 9, 2017, Pages 2189-2201

  Walker, Alec J ^a   Majzner, Robbie G ^b   Zhang, Ling ^a   Wanhainen, Kelsey ^a   Long, Adrienne H ^a   Nguyen, Sang M ^a   Lopomo, Paola ^a   Vigny, Marc ^c   Fry, Terry J ^a   Orentas, Rimas J ^a   Mackall, Crystal L ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INSTITUT DU FER À MOULIN   (France)

Author keywords

ALK; anaplastic lymphoma kinase; antigen density; CAR; chimeric antigen receptor; immunotherapy; neuroblastoma; tumor immunology

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CHIMERIC ANTIGEN RECEPTOR; CYCLOPHOSPHAMIDE; MESSENGER RNA; TUMOR ANTIGEN; CELL SURFACE RECEPTOR; FUSION PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; PROTEIN TYROSINE KINASE;

ALK GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL SURFACE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LYMPHOMA; MALE; MOUSE; NEUROBLASTOMA CELL LINE; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR DENSITY; T LYMPHOCYTE ACTIVATION; ADOPTIVE IMMUNOTHERAPY; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DRUG SCREENING; GENE EXPRESSION; GENE ORDER; GENE VECTOR; GENETICS; IMMUNOLOGY; LENTIVIRUS; LYMPHOCYTE ACTIVATION; METABOLISM; NEOPLASM; T LYMPHOCYTE; TUMOR CELL LINE;

ANIMALS; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENE ORDER; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LENTIVIRUS; LYMPHOCYTE ACTIVATION; MICE; NEOPLASMS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, CELL SURFACE; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85021396664     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1016/j.ymthe.2017.06.008     Document Type: Article

References (62)

1. Palmer, R.H., Vernersson, E., Grabbe, C., Hallberg, B., Anaplastic lymphoma kinase: signalling in development and disease. Biochem. J. 420 (2009), 345–361.
2. Morris, S.W., Kirstein, M.N., Valentine, M.B., Dittmer, K.G., Shapiro, D.N., Saltman, D.L., Look, A.T., Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263 (1994), 1281–1284.
3. Sasaki, T., Rodig, S.J., Chirieac, L.R., Jänne, P.A., The biology and treatment of EML4-ALK non-small cell lung cancer. Eur. J. Cancer 46 (2010), 1773–1780.
4. Chiarle, R., Voena, C., Ambrogio, C., Piva, R., Inghirami, G., The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat. Rev. Cancer 8 (2008), 11–23.
5. Mossé, Y.P., Laudenslager, M., Longo, L., Cole, K.A., Wood, A., Attiyeh, E.F., Laquaglia, M.J., Sennett, R., Lynch, J.E., Perri, P., et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455 (2008), 930–935.
6. George, R.E., Sanda, T., Hanna, M., Fröhling, S., Luther, W. 2nd, Zhang, J., Ahn, Y., Zhou, W., London, W.B., McGrady, P., et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455 (2008), 975–978.
7. Chen, Y., Takita, J., Choi, Y.L., Kato, M., Ohira, M., Sanada, M., Wang, L., Soda, M., Kikuchi, A., Igarashi, T., et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455 (2008), 971–974.
8. Heukamp, L.C., Thor, T., Schramm, A., De Preter, K., Kumps, C., De Wilde, B., Odersky, A., Peifer, M., Lindner, S., Spruessel, A., et al. Targeted expression of mutated ALK induces neuroblastoma in transgenic mice. Sci. Transl. Med., 4, 2012, 141ra91.
9. Zhu, S., Lee, J.S., Guo, F., Shin, J., Perez-Atayde, A.R., Kutok, J.L., Rodig, S.J., Neuberg, D.S., Helman, D., Feng, H., et al. Activated ALK collaborates with MYCN in neuroblastoma pathogenesis. Cancer Cell 21 (2012), 362–373.
10. Passoni, L., Longo, L., Collini, P., Coluccia, A.M., Bozzi, F., Podda, M., Gregorio, A., Gambini, C., Garaventa, A., Pistoia, V., et al. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer Res. 69 (2009), 7338–7346.
11. Schulte, J.H., Bachmann, H.S., Brockmeyer, B., Depreter, K., Oberthür, A., Ackermann, S., Kahlert, Y., Pajtler, K., Theissen, J., Westermann, F., et al. High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma. Clin. Cancer Res. 17 (2011), 5082–5092.
12. Mossé, Y.P., Anaplastic Lymphoma Kinase as a Cancer Target in Pediatric Malignancies. Clin. Cancer Res. 22 (2016), 546–552.
13. Brentjens, R.J., Rivière, I., Park, J.H., Davila, M.L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S., Borquez-Ojeda, O., et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118 (2011), 4817–4828.
14. Brentjens, R.J., Davila, M.L., Riviere, I., Park, J., Wang, X., Cowell, L.G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med., 5, 2013, 177ra38.
15. Grupp, S.A., Kalos, M., Barrett, D., Aplenc, R., Porter, D.L., Rheingold, S.R., Teachey, D.T., Chew, A., Hauck, B., Wright, J.F., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368 (2013), 1509–1518.
16. Lee, D.W., Shah, N.N., Stetler-Stevenson, M., Sabatino, M., Delbrook, C., Richards, K., Kochenderfer, J.N., Rosenberg, S.A., Stroncek, D., Wayne, A.S., Mackall, C.L., Anti-CD19 chimeric antigen receptor (CAR) T cells produce complete responses with acceptable toxicity but without chronic B-cell aplasia in children with relapsed or refractory acute lymphoblastic leukemia (ALL) even after allogeneic hematopoietic stem cell transplantation (HSCT). Blood, 122, 2013, 68.
17. Maude, S.L., Frey, N., Shaw, P.A., Aplenc, R., Barrett, D.M., Bunin, N.J., Chew, A., Gonzalez, V.E., Zheng, Z., Lacey, S.F., et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371 (2014), 1507–1517.
18. Davila, M.L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S.S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med., 6, 2014, 224ra25.
19. Lee, D.W., Kochenderfer, J.N., Stetler-Stevenson, M., Cui, Y.K., Delbrook, C., Feldman, S.A., Fry, T.J., Orentas, R., Sabatino, M., Shah, N.N., et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385 (2015), 517–528.
20. Ahmed, N., Brawley, V.S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., Liu, E., Dakhova, O., Ashoori, A., Corder, A., et al. Human Epidermal Growth Factor Receptor 2 (HER2)-Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. J. Clin. Oncol. 33 (2015), 1688–1696.
21. Louis, C.U., Savoldo, B., Dotti, G., Pule, M., Yvon, E., Myers, G.D., Rossig, C., Russell, H.V., Diouf, O., Liu, E., et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118 (2011), 6050–6056.
22. Pule, M.A., Savoldo, B., Myers, G.D., Rossig, C., Russell, H.V., Dotti, G., Huls, M.H., Liu, E., Gee, A.P., Mei, Z., et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 14 (2008), 1264–1270.
23. Moog-Lutz, C., Degoutin, J., Gouzi, J.Y., Frobert, Y., Brunet-de Carvalho, N., Bureau, J., Créminon, C., Vigny, M., Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin. J. Biol. Chem. 280 (2005), 26039–26048.
24. Carpenter, E.L., Haglund, E.A., Mace, E.M., Deng, D., Martinez, D., Wood, A.C., Chow, A.K., Weiser, D.A., Belcastro, L.T., Winter, C., et al. Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma. Oncogene 31 (2012), 4859–4867.
25. Orentas, R.J., Yang, J.J., Wen, X., Wei, J.S., Mackall, C.L., Khan, J., Identification of cell surface proteins as potential immunotherapy targets in 12 pediatric cancers. Front. Oncol., 2, 2012, 194.
26. Almåsbak, H., Walseng, E., Kristian, A., Myhre, M.R., Suso, E.M., Munthe, L.A., Andersen, J.T., Wang, M.Y., Kvalheim, G., Gaudernack, G., Kyte, J.A., Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model. Gene Ther. 22 (2015), 391–403.
27. Hudecek, M., Lupo-Stanghellini, M.-T., Kosasih, P.L., Sommermeyer, D., Jensen, M.C., Rader, C., Riddell, S.R., Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin. Cancer Res. 19 (2013), 3153–3164.
28. Long, A.H., Haso, W.M., Shern, J.F., Wanhainen, K.M., Murgai, M., Ingaramo, M., Smith, J.P., Walker, A.J., Kohler, M.E., Venkateshwara, V.R., et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat. Med. 21 (2015), 581–590.
29. Haso, W., Lee, D.W., Shah, N.N., Stetler-Stevenson, M., Yuan, C.M., Pastan, I.H., Dimitrov, D.S., Morgan, R.A., FitzGerald, D.J., Barrett, D.M., et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood 121 (2013), 1165–1174.
30. Long, A.H., Highfill, S.L., Cui, Y., Smith, J.P., Walker, A.J., Ramakrishna, S., El-Etriby, R., Galli, S., Tsokos, M.G., Orentas, R.J., Mackall, C.L., Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas. Cancer Immunol. Res. 4 (2016), 869–880.
31. Hooijberg, E., Bakker, A.Q., Ruizendaal, J.J., Spits, H., NFAT-controlled expression of GFP permits visualization and isolation of antigen-stimulated primary human T cells. Blood 96 (2000), 459–466.
32. Zhang, L., Kerkar, S.P., Yu, Z., Zheng, Z., Yang, S., Restifo, N.P., Rosenberg, S.A., Morgan, R.A., Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol. Ther. 19 (2011), 751–759.
33. Jena, B., Maiti, S., Huls, H., Singh, H., Lee, D.A., Champlin, R.E., Cooper, L.J., Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials. PLoS ONE, 8, 2013, e57838.
34. Janoueix-Lerosey, I., Lequin, D., Brugières, L., Ribeiro, A., de Pontual, L., Combaret, V., Raynal, V., Puisieux, A., Schleiermacher, G., Pierron, G., et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455 (2008), 967–970.
35. Weijtens, M.E., Hart, E.H., Bolhuis, R.L., Functional balance between T cell chimeric receptor density and tumor associated antigen density: CTL mediated cytolysis and lymphokine production. Gene Ther. 7 (2000), 35–42.
36. Turatti, F., Figini, M., Balladore, E., Alberti, P., Casalini, P., Marks, J.D., Canevari, S., Mezzanzanica, D., Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction. J. Immunother. 30 (2007), 684–693.
37. James, S.E., Greenberg, P.D., Jensen, M.C., Lin, Y., Wang, J., Till, B.G., Raubitschek, A.A., Forman, S.J., Press, O.W., Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. J. Immunol. 180 (2008), 7028–7038.
38. Anurathapan, U., Chan, R.C., Hindi, H.F., Mucharla, R., Bajgain, P., Hayes, B.C., Fisher, W.E., Heslop, H.E., Rooney, C.M., Brenner, M.K., et al. Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. Mol. Ther. 22 (2014), 623–633.
39. Caruso, H.G., Hurton, L.V., Najjar, A., Rushworth, D., Ang, S., Olivares, S., Mi, T., Switzer, K., Singh, H., Huls, H., et al. Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity. Cancer Res. 75 (2015), 3505–3518.
40. Watanabe, K., Terakura, S., Martens, A.C., van Meerten, T., Uchiyama, S., Imai, M., Sakemura, R., Goto, T., Hanajiri, R., Imahashi, N., et al. Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ζ chimeric antigen receptor-modified effector CD8+ T cells. J. Immunol. 194 (2015), 911–920.
41. Hombach, A.A., Görgens, A., Chmielewski, M., Murke, F., Kimpel, J., Giebel, B., Abken, H., Superior therapeutic index in lymphoma therapy: CD30(+) CD34(+) hematopoietic stem cells resist a chimeric antigen receptor T-cell attack. Mol. Ther. 24 (2016), 1423–1434.
42. Hegde, M., Mukherjee, M., Grada, Z., Pignata, A., Landi, D., Navai, S.A., Wakefield, A., Fousek, K., Bielamowicz, K., Chow, K.K., et al. Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape. J. Clin. Invest. 126 (2016), 3036–3052.
43. Itoh, Y., Germain, R.N., Single cell analysis reveals regulated hierarchical T cell antigen receptor signaling thresholds and intraclonal heterogeneity for individual cytokine responses of CD4+ T cells. J. Exp. Med. 186 (1997), 757–766.
44. Alvarez-Vallina, L., Russell, S.J., Efficient discrimination between different densities of target antigen by tetracycline-regulatable T bodies. Hum. Gene Ther. 10 (1999), 559–563.
45. James, S.E., Greenberg, P.D., Jensen, M.C., Lin, Y., Wang, J., Budde, L.E., Till, B.G., Raubitschek, A.A., Forman, S.J., Press, O.W., Mathematical modeling of chimeric TCR triggering predicts the magnitude of target lysis and its impairment by TCR downmodulation. J. Immunol. 184 (2010), 4284–4294.
46. Huang, J., Brameshuber, M., Zeng, X., Xie, J., Li, Q.J., Chien, Y.H., Valitutti, S., Davis, M.M., A single peptide-major histocompatibility complex ligand triggers digital cytokine secretion in CD4(+) T cells. Immunity 39 (2013), 846–857.
47. Srivastava, S., Riddell, S.R., Engineering CAR-T cells: Design concepts. Trends Immunol. 36 (2015), 494–502.
48. Ciardiello, C., Roca, M.S., Noto, A., Bruzzese, F., Moccia, T., Vitagliano, C., Di Gennaro, E., Ciliberto, G., Roscilli, G., Aurisicchio, L., et al. Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression. Oncotarget 7 (2016), 19559–19574.
49. Shimizu, R., Kikuchi, J., Wada, T., Ozawa, K., Kano, Y., Furukawa, Y., HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells. Leukemia 24 (2010), 1760–1768.
50. Liu, X., Jiang, S., Fang, C., Yang, S., Olalere, D., Pequignot, E.C., Cogdill, A.P., Li, N., Ramones, M., Granda, B., et al. Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice. Cancer Res. 75 (2015), 3596–3607.
51. Davenport, A.J., Jenkins, M.R., Cross, R.S., Yong, C.S., Prince, H.M., Ritchie, D.S., Trapani, J.A., Kershaw, M.H., Darcy, P.K., Neeson, P.J., CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells. Cancer Immunol. Res. 3 (2015), 483–494.
52. Song, D.-G., Ye, Q., Poussin, M., Liu, L., Figini, M., Powell, D.J. Jr., A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity. Oncotarget 6 (2015), 21533–21546.
53. Escors, D., Bricogne, C., Arce, F., Kochan, G., Karwacz, K., On the Mechanism of T cell receptor down-modulation and its physiological significance. J. Biosci. Med., 1, 2011, 2011.5.
54. Finetti, F., Onnis, A., Baldari, C.T., Regulation of vesicular traffic at the T cell immune synapse: lessons from the primary cilium. Traffic 16 (2015), 241–249.
55. Rachmilewitz, J., Lanzavecchia, A., A temporal and spatial summation model for T-cell activation: signal integration and antigen decoding. Trends Immunol. 23 (2002), 592–595.
56. Faroudi, M., Utzny, C., Salio, M., Cerundolo, V., Guiraud, M., Müller, S., Valitutti, S., Lytic versus stimulatory synapse in cytotoxic T lymphocyte/target cell interaction: manifestation of a dual activation threshold. Proc. Natl. Acad. Sci. USA 100 (2003), 14145–14150.
57. Huppa, J.B., Davis, M.M., T-cell-antigen recognition and the immunological synapse. Nat. Rev. Immunol. 3 (2003), 973–983.
58. Au-Yeung, B.B., Zikherman, J., Mueller, J.L., Ashouri, J.F., Matloubian, M., Cheng, D.A., Chen, Y., Shokat, K.M., Weiss, A., A sharp T-cell antigen receptor signaling threshold for T-cell proliferation. Proc. Natl. Acad. Sci. USA 111 (2014), E3679–E3688.
59. Hoffmann, D., Schott, J.W., Geis, F.K., Lange, L., Müller, F.J., Lenz, D., Zychlinski, D., Steinemann, D., Morgan, M., Moritz, T., Schambach, A., Detailed comparison of retroviral vectors and promoter configurations for stable and high transgene expression in human induced pluripotent stem cells. Gene Ther. 24 (2017), 298–307.
60. Kettleborough, C.A., Saldanha, J., Ansell, K.H., Bendig, M.M., Optimization of primers for cloning libraries of mouse immunoglobulin genes using the polymerase chain reaction. Eur. J. Immunol. 23 (1993), 206–211.
61. Sanjana, N.E., Shalem, O., Zhang, F., Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 11 (2014), 783–784.
62. D'hautcourt, J.L., Quantitative flow cytometric analysis of membrane antigen expression. Curr. Protoc. Cytom., Chapter 6, 2002, Unit 6.12.